Big Pharma vet teams with former Doudna pupil to launch new epigenome startup
A former doctoral candidate in CRISPR pioneer Jennifer Doudna’s lab founded a new biotech seeking to wade into “epigenetics-level gene editing,” and has now secured enough capital to do just that.
The new San Francisco startup, Epic Bio, put out word early Tuesday that it had officially launched, securing a Series A worth $55 million. That should be enough to fund the biotech’s dash towards the clinic, and CEO Amber Salzman tells Endpoints News the goal is to reach it by the end of next year.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 147,200+ biopharma pros reading Endpoints daily — and it's free.